Skip to main content

NeuroPace Inc

NPCE
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001528287

In the last 90 days, NeuroPace Inc insiders filed 3 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q3 2026, worth $369.0M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 18, 2026
$283.2M
Insider buysLast 90 days, $302.1K in total
3
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, −6 vs. previous quarter
104
13F valueReported value at the end of Q3 2026
$369.0M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$100.0M
+25.1% year over year
Net income, FY2025
-$21.5M
No comparable prior period
Free cash flow, FY2025
-$11.3M
No comparable prior period
Revenue, Q3 FY2026
$23.1M
−15.5% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $21.5M (21.5% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
858.3K
Shares sold short
Change
−27.9K
−3.2% vs. previous
Days to cover
8.48
At average daily volume

Superinvestors holding NPCE, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding NPCE at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by NeuroPace Inc insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 18, 2026 (view filing)5:09 PM ETNov 18Same dayHuennekens R ScottDirectorPPurchase+12.5K$8.29+$103.7KNew position12.5K after
Nov 17, 2026 (view filing)5:10 PM ETNov 17Same dayWilliams Patrick F.Chief Financial OfficerPPurchase+11.9K$8.34+$99.1K+17.6%79.4K after
Nov 17, 2026 (view filing)5:08 PM ETNov 17Same dayBecker JoelCHIEF EXECUTIVE OFFICERPPurchase+11.9K$8.35+$99.3K+8.6%149.9K after
Mar 4, 2026 (view filing)Dec 15, 202579 daysLateMorrell MarthaCHIEF MEDICAL OFFICERSSale−25.0K$15.97−$399.3K−33.3%50.0K after
May 16, 2025 (view filing)5:26 PM ETMay 142 daysOrbiMed Advisors LLC and 1 other10% OwnerSSale−168.1K$15.85−$2.67M−4.9%3.24M after2 lots
Feb 25, 2025 (view filing)Feb 214 daysMorrell MarthaCHIEF MEDICAL OFFICERSSale−78.3K$13.72−$1.07M−48.9%82.0K after
Feb 20, 2025 (view filing)Feb 20Same dayKCK Ltd.10% OwnerSSale−5.27M$9.40−$49.5M−100.0%0 after
Jan 31, 2025 (view filing)Jan 29-302 daysMorrell MarthaCHIEF MEDICAL OFFICERSSale−300$15.00−$4.50K−0.3%86.8K after2 lots10b5-1
Jan 28, 2025 (view filing)Jan 244 daysMorrell MarthaCHIEF MEDICAL OFFICERSSale−3.20K$15.01−$48.0K−3.5%87.1K after10b5-1
Oct 28, 2024 (view filing)Oct 23-255 daysLateKCK Ltd.10% OwnerSSale−224.1K$5.45−$1.22M−4.1%5.27M after2 lots

Top 10 13F holders, Q3 2026

See all 104 holders

The largest institutional positions in NeuroPace Inc at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding NPCE in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
First Light Asset Management, LLC3,983,577$54.8M3.25%+1,122,410+39.2%Added
Polar Capital Holdings Plc3,298,104$45.4M0.13%00.0%Unchanged
Soleus Capital Management, L.P.3,218,000$44.3M1.57%+306,878+10.5%Added
Morgan Stanley2,568,872$35.3M0.00%−85,519−3.2%Reduced
BlackRock, Inc.2,467,499$34.0M0.00%−10,104−0.4%Reduced
Driehaus Capital Management LLC1,429,439$19.7M0.14%−17,952−1.2%Reduced
Vanguard Capital Management LLC1,234,175$17.0M0.00%+7,103+0.6%Added
OrbiMed Advisors LLC1,055,125$14.5M0.27%−450,000−29.9%Reduced
Deutsche Bank AG935,652$12.9M0.00%−3,267−0.3%Reduced
Armistice Capital, LLC800,000$11.0M0.37%+108,000+15.6%Added

Holders of 5% or more of NPCE

See all 5 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of NeuroPace Inc.

Largest holders of NPCE from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
First Light Asset Management, LLC13G/A12.25%4.20M shares+3.58 ppfrom 8.67%May 15, 20262 filingsSep 4, 2026SEC
Polar Capital Holdings Plc13G9.13%2.97M sharesNewMay 15, 20251 filingMay 15, 2025SEC
Soleus Private Equity Fund I, L.P.13G/A8.90%2.96M shares–Nov 1, 20216 filingsNov 7, 2025SEC
Morgan Stanley13G/A8.30%2.49M shares–Feb 10, 20233 filingsFeb 4, 2025SEC
Soleus Capital Master Fund, L.P.13G/A7.00%2.30M shares–Aug 5, 20251 filingAug 5, 2025SEC